STRATIFICATION OF INDIVIDUALS FOR PET AMYLOID POSITIVITY AND ALZHEIMER’S DISEASE RISK USING POLYGENIC RISK SCORE ANALYSIS: NEW OPPORTUNITIES FOR CLINICAL TRIAL DESIGN